INTRODUCTION
The acute inflammatory response is mediated by a variety of factors which either increase vascular permeability or lead to the leukotactic accumulation of neutrophils. The mediators themselves are chemically diverse, ranging from peptides (the kinins, anaphylatoxins, and chemotactic factors) to substances of very low (< 1,000) molecular weight (e.g. the vasoactive amines). As typified by the complement-derived leukotactic factors (from the third, C3, and fifth, C5 components of complement), a diversity exists not only in structure but also in the generation of these inflammatory mediators. For example, C3 and C5 can be cleaved productive of anaphylatoxin and leukotactic fragments not only by enzymes intrinsic to the complement system, but also by Received for publication 22 August 1972 and in revised form 26 October 1972. enzymes extrinsic to complement, such as plasmin, trypsin, thrombin, and tissue derived neutral proteases (reviewed in 1).
In spite of the remarkable diversity of mediators, the inflammatory response is kept in balance by naturally occurring inhibitors. For instance, the kinins and the anaphylatoxins are destroyed almost immediately upon generation in serum. This phenomenon of inactivation has been related to the existence in serum of a carboxypeptidase B enzyme that inactivates the kinins and the anaphylatoxins by removal of the C-terminal arginine residue in the peptides (2) . In this report we describe the presence in normal human serum of a chemotactic factor inactivator. It seems likely that the function of this inactivator is to provide regulatory control over the leukotactic mediators generated in serum.
METHODS
Chemotactic assays. Chemotaxis was performed by the micropore filter technique in modified Boyden chambers. This technique has been previously described in detail (3, 4) . Filters of 0.65 gm pore size (Millipore Corp., Bedford, Mass.) were used and chemotactic activity quantitated by counting the numbers of cells which had migrated through channels of filters in five high power fields under light microscopy. Rabbit neutrophils from glycogen-induced peritoneal exudates were the indicator cells. The upper compartment of each chemotaxis chamber contained a total of 2.5 X 106 neutrophils in 0.1% bovine serum albumin (BSA).
The bottom compartment of each chamber contained the fluids to be tested for chemotactic activity. Hank's medium (Microbiological Associates, Inc., Bethesda, Md.) was used for dilution of both cells and fluids. For convenience, rabbit neutrophils were the usual indicator cell. However, the results tested in Tables I, II , and IV were reproduced using human neutrophils as the indicator cells. Only the data obtained with rabbit neutrophils are listed in this report.
In all cases where studies of the chemotactic factor were carried out, the chemotactic factor inactivator was mixed with 50 dAI Escherichia coli bacterial factor (see below) or other chemotactic factors, as indicated. After incubation at room temperature for 30 min, this mixture was adjusted to 1.0 ml with Hank's medium and the chemotactic assay carried out. Per cent inhibition was determined by calculat-ing the ratio of chemotactic activity in the presence of the inactivator and in its absence, times 100 and subtracting from 100. P'reparation of clhemotactic bacteria: bacterial factor was ohtained from culture supernatants (in 1-ank's medium) of E. coli sterilized by filtration through a Micropore filter (5) . 50 ul of this factor were used as the standard source of chemotactic factor unless otherwise indicated.
Preparation of complement cilemnotactic factors. Human C3 and C5 were purified according to the method of Nilsson and Mfiller-Eberhard (6), which included a combination of isoelectric precipitation, ion exchange chromatography, hydroxyl apatite chromatography, and preparative electrophoresis. Chemotactic fragments of C3 were produced by treatment with trypsin (Mann Research Labs., Inc., New York) according to the procedure of Bokisch and MullerEberhard (2) . Chemotactic fragments of C5 were obtained in a similar manner (7) . Except where indicated, these solutions were not fractionated further. In one experiment 1 mg unlabeled C5, mixed with 0.1 mg radiotagged C5 (by the iodine monochloride method, 12), was treated with 100 ,ug trypsin (in a reaction volume of 0.5 ml) at 320C X 20 min. The reaction was stopped by addition of 200 /Ag soybean trypsin inhibitor (Mann Research Labs., Inc.) contained in a volume of 50 A1 in phosphate-buffered saline.
The trypsinized (and chemotactically active) C5 material was then fractionated by gel filtration, as described below. A zone of radioactivity near the void volume of the eluted column was found, as well as one near the cytochrome marker. The radioactivity in the latter zone was pooled and used as the source of chemotactically active CS fragment (7) . Human C567, activated by trypsin treatment of C567 (8) in an International Hematocrit Centrifuge (International Equipment Co., Boston, Mass.), B-60 using a swinging bucket rotor (4). Gel chromatography was carried out with Biogel P200 (Bio-Rad Laboratories, Richmond, Calif.) in phosphate-buffered saline. The proteins human IgG, BSA, and cytochrome c were used as markers in ultracentrifugal and gel filtration techniques. The same markers have been used previously (7) .
RESULTS
Salt fractionation of chemtotactic factor inactivator.
When the bacterial factor from E. coli was treated with 100 al whole human serum no significant loss of chemotactic activity was noted (Table I) . At the present time at least 20 different whole normal human sera have been tested and found to be lacking in ability to inhibit chemotactic activity. However, when the various ammonium sulfate fractions from each of two sera were studied, it was found that the soluble fraction of serum was sig- FRACTIONS FIGURE 1 Patterns of chemotactic factor inactivator in ammonium sulfate-soluble fractions from two normal human sera, separated by density gradient ultracentrifugation. 50 ,al bacterial chemotactic factor was incubated with each fraction from the gradients at 25'C X i h, the mixture then assayed for residual chemotactic activity. In each of the preparations two zones of inhibitor are present.
nificantly inhibitory for the chemotactic factors when appropriate volumes were used. No inhibitory activity could be demonstrated in the redissolved precipitate, indicating that the chemotactic factor inactivator is associated with a fraction of serum other than the Ig-rich fraction. Direct action of inactivator on the chemotactic factor. These experiments were designed to determine if the inactivator was directly affecting the chemotactic factors or the indicator leukocytes. Using the ammonium sulfate soluble (concentrated) fraction from normal serum (Table III) . When the inactivator was added to the boiled bacterial chemotactic factor, 63% loss of chemotactic activity resulted. The prior boiling of the inactivator abolished most of the inhibitory effect on chemotactic activity (Table III, 15% loss), whereas boiling the mixture of inactivator and chemotactic factor (after they had been incubated together) failed to restore the chemotactic activity (59% loss). These results indicate that the chemotactic factor inactivator acts in an irreversible manner on the bacterial chemotactic factor to render it inactive.
Broad spectrum of activity of inactivator on chemotactic factors. The previous experiments indicated that the inactivator present in the soluble (and concentrated) fraction of ammonium sulfate-treated human serum could inactivate the bacterial chemotactic factor. The data in Table IV (Fig. 2) . Two zones of inhibitor activity were demonstrated: the first eluted between the IgG and BSA markers, and the second near the cy}tochrome c marker. As with the ultracentrifugal fractionation, these data indicate a heterogeneity in the characteristics of the chemotactic factor inactivator. In experiments not listed here rechromatography of each of the two zones of chemotactic factor inactivator has resulted in the same chromatographic position of each inactivator as in the original separation. This finding together with those to be presented below suggests that the heterogeneity of the inactivator is due to two separate and distinct substances.
Electrophoretic separation of the inactivator. 8 ml normal human serum not previously fractionated was electrophoresed in a Pevikon block at pH 8.6 and the fractions (100 nml each) tested for ability to inhibit the bacterial chemotactic factor was found to be present in two zones corresponding to a-and P-globulin positions. (Fig. 3) . To what extent these two zones of inactivator relate to the two zones found by ultracentrifugation and gel filtration (Figs. 1 and 2) is not known. Aiechamisins of action/ of clheinotactic factor inactivator. None of the preceding experiments defined the mechanism by which the inactivator interacts with chemiotactic factors to render them inactive. To study this question. the trypsin produced (and radio-labeled) CD fragment was isolated and then incubated with the inactivator. The source of the inactivator was the material eluting near the IgG marker front a Biogel column (Fig. 2) . This inactivator was concentrated to a volume of one-third the original serum volume. 10 Ol inacti-ator was incubated with 50 /4 C5 fragment (equivalent to approximately 5 tug original CS) at room temperature for 20 min, and then ultracentrifuged. The results are seen in Fig. 4 . Neither the amounts of radioactivity in the gradient nor the position of the radioactivity seemed altered as a result of inactivation (Fig. 4 , when compared with the pattern for t chemotactic fragment (Fig. 4, solid line) . tests of the various fractions showed the high levels of activity in fractions 12-14 whereas chemotactic activity in the same lost as a result of pretreatment of the C5 f the inactivator (Table V) . It should be po in the preparation of C5 fragment trea inactivator a small zone of radioactivity wE ultracentrifugal position of the inactivator tions 8 and 9). The significance of the sm radioactivity ('-4% of total radioactivit fragment preparation) is unknown. Whi] rule out a highly reversible interaction, th gest that however the inactivator alters the it is probably not due to substantial, irreve to the chemotactic factor.
DISCUSSION
The data presented in this paper indica exists in normal human serum an inactiva tactic factors. This inactivator is heterog4 by a variety of fractionation techniques, appears in two positions. The chemotac activator acts directly and irreversibly o tactic factor, and it has a broad spectrui inactivating C567, the chemotactic fragme' C5, and the bacterial chemotactic factor E. coli. It is not possible to completely ex sibility that some of the effect of the chemotactic factor inactivator is cell-directed, but the bulk of the evidence from these studies strongly suggests otherwise. It should be noted that normal human serum contains this inactivator, but the amount present is usually too low to detect in the absence of any fractionation and/or con-FRAGMENT centration procedures. These would explain why it is possible to chemotactically activate normal human serum with agents that trigger the complement system, in spite c5 FAGMENT of the fact that chemotactic factor inactivator exists in INACTIVATOR the serum. The mechanism by which the inactivator interacts with the chemotactic factor is not precisely known. The data in Fig. 4 and Table V do not permit an unambiguous conclusion regarding the mechanism by which the 6 chemotactic factor inactivator abolishes the chemotactic activity. It can be clearly stated that this is through a by ultracen-direct effect on the chemotactic factor rather than by an Ily active C5 effect on leukocytes. A major question arising from these studies concerns the relationship of the inhibitor of chemotactic factors and the anaphylatoxin inactivator (AI) 1 described by Bokisch et al. (2) . AI is a pseudoglobin with an electrophoretic mobility of an a-globulin, a molecular weight of 325,000, and is present in normal human serum. This inactivator has carboxypeptidase B activity and largely accounts for the ability of normal human serum to rapidly destroy the kinins generated by kallikrein and the anaphylatoxin peptides C3a and C5a. To what extent are AI and the inactivator of chemotactic factor identical? On the basis of the data presented in this paper there are some similarities between the two inhibitors. On the other hand, there are several significant differences. As shown by ultracentrifugal, electrophoretic, and molecular sieving techniques, the chemotactic factor inhibitor is heterogenous, consisting of two different substances. Bokisch et al. (2) (2) . The resolution of the basic question about identity or nonidentity of AI and the chemotactic factor inactivator must await availability 1Abbreviation used in this paper: AI, anaphylatoxin inactivator.
of a highly purified preparation of the latter. In part, the difficulty in resolving this question relates to the unknown chemical relationship between the chemotactic peptides of C3 and C5 and the homologous anaphylatoxins, C3a and C5a. There is highly suggestive evidence in favor of the nonidentity of the homologous peptides with anaphylatoxin and chemotactic function. Although treatment of purified C3 and C5 with trypsin leads to the production of fragments with anaphylatoxin and chemotactic activity, continued treatment with trypsin results in the disappearance of anaphylatoxin, whereas there is no demonstrable loss in chemotactic activity (17, 18) . Since there is a fundamental question regarding structure relationship between the anaphylatoxins and the chemotactic factors, extrapolations between the data from AI and those of the chemotactic factor inactivator are difficult. Furthermore, it should be pointed out that while human serum cannot be activated to produce anaphylatoxin (2, 17) , there is little difficulty in activating human serum with an immune complex so as to generate chemotactic activity (3, 4) . These findings indicate that chemotactic activity which is generated in human serum by complement activating substances is resistant to the effects of inactivators naturally present in serum, either because the chemotactic factors are not susceptible to the inactivators, or because they are generated in quantities too great to be handled by the levels of inactivators. Whatever the case may be, the ability to generate chemotactic activity in human serum certainly stands in sharp contrast to that inability to generate anaphylatoxin activity in whole human serum. It should be stressed that, while some obvious differences exist between AI and the serum inhibitor of chemotactic factors, as revealed by fractionation procedures, there is no definitive answer to the question of identity or nonidentity of the two inactivators. Perhaps the most relevant point in our data is the demonstration of a naturally occurring chemotactic factor inactivator in human serum. Data will be presented in a subsequent paper to show the presence of this inactivator in super-normal amounts in pathologic human sera.
The problem of a better assay for the chemotactic factor inactivator is obvious. When the inactivator is sufficiently purified, it should be feasible to develop an immunochemical assay that would allow detection of the inactivator in whole serum. Alternatively, when the structural definitions of the various chemotactic factors are obtained, it is possible that this information can be translated into chemical changes in the chemotactic factors reflecting the action of the chemotactic factor inactivator. For the present, however, the functional assay will remain.
